Top

Pipeline

  • Product Candidate
  • Target
  • Indication
  • Differentiation
  • Lead Selection
  • IND
  • Phase I
  • Phase II

  • MT-3724
  • CD20
  • B-Cell Malignancies
  • CD20 Internalization


  • 82

  • MT-4019
  • CD38
  • Multiple Myeloma
  • Cell-Kill on CD38low, CD55/CD59high Tumors


  • 42

  • MT-2289
  • HER2
  • Breast
  • Antigen Seeding


  • 37

  • MT-5050
  • PD-L1
  • Melanoma
  • Antigen Seeding


  • 25

  • MT-6868
  • CD45
  • SCT
  • Non-Chemo


  • 25